Close Menu

NEW YORK – BioMarin has chosen PerkinElmer to provide testing in support of the biopharmaceutical firm's sponsored testing program for patients in Mexico, PerkinElmer said on Wednesday.

Specifically, the testing program is aimed at Batten disease and mucopolysaccharidosis (MPS)  disorders and is designed to help patients and clinicians by providing tests for identifying MPS IVA, also called Morquio A syndrome; MPS VI, or Maroteaux-Lamy syndrome; and CLN2, or late infantile neuronal ceroid lipofuscinosis type 2 disease.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.